Center for Clinical and Translational Science

临床和转化科学中心

• 批准号: 10265619
• 负责人: Robert P. Kimberly
• 金额: $ 80.71万
• 依托单位: UNIVERSITY OF ALABAMA AT BIRMINGHAM
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-11-01 至 2021-10-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10265619
• 关键词: 2019-nCoV; Academic Medical Centers; Adult; Alabama; Antibodies; Antibody titer measurement; Applied Research; Basic Science; Biological Assay; Biological Markers; Blood specimen; COVID-19; COVID-19 diagnosis; COVID-19 outbreak; COVID-19 pandemic; Clinical; Clinical Sciences; Clinical and Translational Science Awards; Communicable Diseases; Community Health; Consent; Country; Data; Development; Diagnosis; Disease Outbreaks; Economics; Enrollment; Future; General Population; Goals; Health; Herd Immunity; Humoral Immunities; Immune; Immune response; Immunity; Incidence; Individual; Infection; Infectious Diseases Research; Institutes; Intramural Research Program; Knowledge; Life Cycle Stages; Molecular Biology; Molecular Genetics; Morbidity - disease rate; National Institute of Allergy and Infectious Disease; Natural History; Outcome; Participant; Phase; Population; Prevalence; Preventive; Public Health; Public Health Practice; Role; SARS-CoV-2 antibody; SARS-CoV-2 immunity; Sampling; Seroprevalences; Serum; Special Population; Testing; Time; Translational Research; Underrepresented Populations; United States; United States National Institutes of Health; Universities; Vaccines; Viral; Viral Vaccines; Virus; Work; antibody detection; antibody test; clinical center; cohort; eligible participant; immunological status; insight; mortality; novel; pandemic disease; pathogen; phase 2 study; response; screening; social; vaccine development

ABSTRACT The pandemic prompted by the novel SARS-COV-2 virus continues to have a devastating impact on the health of communities, clinically, socially and economically. Preventive approaches require an understanding of the virus prevalence and the level of herd immunity in the general population. As part of a previous natural history study, the Center for Clinical and Translational Science (CCTS; University of Alabama at Birmingham [UAB]) collaborated with the University of Pittsburgh Clinical and Translational Science Institute (CTSI) and the National Institute of Allergy and Infectious Diseases (NIAID) Laboratory of Infectious Disease (LID) to coordinate a national COVID-19 seroprevalence project. This study established a near-representative, nation- wide cohort of 11,300 participants who had not been diagnosed with the virus to provide biospecimens to evaluate baseline immunity across the United States. To examine the time-dependent population prevalence of detectable antibodies to SARS-COV-2, this scientific partnership of academic medical centers and the NIH’s intramural research program will recall and re-consent the established cohort to submit additional blood specimens and clinical information at 6- and 12-month time points from their original enrollment date to understand changes in COVID-19 immunity across the country (Aim 1). Newly obtained biospecimens will be used to determine the immune attributes associated with health outcomes, including outcomes in special or underrepresented populations and individuals across the life course (Aim 2). This work benefits from the deep expertise in the basic and applied research of infectious diseases as well as viral vaccine development, host immune response to viruses, and viral molecular biology and genetics at the National Institute for Allergy and Infectious Diseases (NIAID). It also leverages the rigorous and efficient capacity maintained by Clinical and Translational Science Awards (CTSA) Hubs at UAB and Pittsburgh to rapidly engage diverse cohorts of participants nationally to accelerate translational research that is high priority scientifically and for eventual public health practice. From this study, the collaborative team will gain crucial insights into the longitudinal impact of the COVID-19 pandemic across the country and will identify potential targets for a vaccine. These data are essential to assess the impact of public health efforts and to guide ongoing COVID-19 response.

抽象的 新型SARS-COV-2病毒引起的大流行对健康仍具有毁灭性影响 在临床，社会和经济上的社区。预防方法需要了解 病毒患病率和普通人群中的牛群免疫水平。作为以前自然历史的一部分 研究，临床与转化科学中心（CCTS；伯明翰阿拉巴马大学[UAB]） 与匹兹堡大学临床与转化科学研究所（CTSI）和 国家过敏和传染病研究所（NIAID）传染病实验室（LID） 协调一个国家Covid-19 Serapravalence项目。这项研究建立了一个近乎代表性的国家 尚未被诊断为病毒的11,300名参与者组成的大量队列，以提供生物测量 评估整个美国的基线免疫力。检查时间依赖于时间的人口流行率 SARS-COV-2的可检测抗体，该学术医疗中心的科学伙伴关系和NIH的抗体 壁内研究计划将回忆并重新介绍已建立的同类同类，以提交额外的血液 从其原始注册日期到6个月和12个月的标本和临床信息 了解全国各地的Covid-19免疫力的变化（AIM 1）。新获得的生物测量将是 用于确定与健康结果相关的免疫属性，包括特殊或 人生过程中代表性不足的人群和个人（AIM 2）。这项工作从深处受益 在传染病以及病毒疫苗开发的基本和应用研究方面的专业知识，宿主 美国国家过敏研究所对病毒以及病毒分子生物学和遗传学的免疫反应 传染病（NIAID）。它还利用临床和 UAB和匹兹堡的转化科学奖（CTSA）枢纽，以迅速与潜水员队列接触 在全国范围内，参与者加速了从科学上优先考虑的转化研究 公共卫生实践。从这项研究中，协作团队将获得对纵向的重要见解 联盟19日大流行的影响，并将确定疫苗的潜在靶标。这些 数据对于评估公共卫生工作的影响至关重要，并指导正在进行的Covid-19反应。